This retrospective analysis demonstrates that incorporating CXCR4-directed ERT with TBI and chemotherapy is feasible and results in promising response rates for patients with AML refractory to multiple lines of therapy. This evidence concerns the gene CXCR4 and acute myeloid leukemia.